# Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

> **NCT01323478** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 71 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine (Lu AA21004)

## Key facts

- **NCT ID:** NCT01323478
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323478, "Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01323478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*